Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Transl Stroke Res. 2020 Mar 20;12(1):112–124. doi: 10.1007/s12975-020-00807-y

Fig.3. CD133+Exo treatment reduces body weight and blood glucose but does not improve cardiac function in T2DM mice.

Fig.3

a) Representative images of M-mode transthoracic echocardiography measurements in short-axis view. b) CD133+Exo treatment in T2DM mice does not significantly affect cardiac function evaluated by echocardiography at 1 month after treatment. c) CD133+Exo treatment in T2DM mice significantly decreases body weight and blood glucose compared to baseline values as well as T2DM sham mice at 1 month. T2DM: n=10; T2DM+CD133+Exo: n=7